« April 2008 | Main | June 2008 »

May 2008

May 30, 2008

Macnification Manages Digital Electron Microscopy Workflow

Orbicule announced the launch and immediate availability of Macnification on Tuesday. The new software allows the scientist to import, organize, find, annotate, analyze, adjust, compare, visualize and publish microscopic images.

"All major image file formats can be imported into Macnification, in addition to many proprietary formats including e.g. Gatan Digital Micrograph (dm3), JEOL SEM images (tiff + txt), MetaMorph Stack (stk), Open Microscopy Environment (ome.tiff) and Zeiss (lsm). Support for more formats is forthcoming. Metdatata is imported as well, and can be viewed and edited in a fully customizable metadata view," Peter Schols said.

The full screen image allows for the various kinds of measurements of the display, and results can be exported to spreadsheet apps, including Numbers, with a single click. The entire workflow is non-destructive of the original image.

The application was written from the ground up for Leopard and takes advantage of Core Animation when viewing virtual cuts. It also leverages Core Image to offer the fastest Extended Depth of Focus (EFI) algorithm of any platform. "In addition, Macnification integrates tightly with Quick Look, Spotlight, Time Machine, Core Data, ImageKit, QuickTime, and many other Mac OS X technologies. It takes full advantage of multiple processor cores," Mr. Scholl added.

Macnification requires Mac OS X 10.5, Leopard, and is priced at €249 (about US$400). A free 30-day trial is available.

Snap1

May 29, 2008

Government Gene Guru Resigns

May 28 (Bloomberg) -- Francis Collins, who led the U.S. government effort to decode the body's DNA blueprint, will step down as head of the National Human Genome Research Institute effective Aug. 1, the agency said.

Collins, 58, helped identify the gene linked to cystic fibrosis in 1989, and in 1993 helped identify DNA tied to Huntington's disease. That same year, Collins was named head of the Human Genome Project and, in 2001, the project published a first draft that identified all 2 billion or so letters that make up the human genetic code.

By providing access to the full catalogue of human genes, scientists have been able to identify variations linked with common and inherited diseases. Researchers have used those results to create medicines such as Tarceva, the Genentech Inc. lung cancer drug developed after a DNA mutation was found to be linked to the tumors. Variations in more than 100 genes have been linked to about 20 diseases, researchers have said.

"The study of the human genome has completely transformed medical research, and is on the way to transforming clinical practice,'' Collins said in a telephone interview today, when asked what he is proudest of from his tenure at the National Institutes of Health.

Alan Guttmacher, the institute's current deputy director, will become acting director on Aug. 1, said NIH director Elias Zerhouni in am e-mailed statement announcing Collins' decision to leave the agency.

`No Heir Apparent'

Bert Vogelstein, professor of oncology and pathology at the Johns Hopkins School of Medicine in Baltimore, said there is "no heir apparent, no one who can easily swoop into the void'' left by Collins' departure. " Francis has both the scientific credentials and an amazing ability to bring people together,'' Vogelstein said. ``He could really explain what was important in understandable terms.''

In the late 1990s and early 2000s, Collins' institute raced against a private company, Celera Genetics, led by Craig Venter, to be the first to publish the genome. A full analysis was completed by Collins' group in April 2003.

Collins, who grew up on a small farm in Virginia and was home-schooled until the sixth grade, got an undergraduate degree in chemistry from the University of Virginia, a doctorate in physical chemistry for Yale University and medical degree from the University of North Carolina. He served on the faculty at the University of Michigan until joining the NIH in 1993.

While at Michigan, he collaborated with researchers at the Hospital for Sick Children in Toronto, Canada, on the gene for cystic fibrosis and Huntington's.

`Insights'

Collins' work at the institute made him "an extraordinary leader in developing tools and applications and insights into what makes us who we are,'' said W. Ian Lipkin, a professor of epidemiology at Columbia University's Mailman School of Public Health in New York, in a telephone interview.

Lipkin was the first to identify the West Nile Virus in the U.S. using genetic technology, and recently isolated one of the causes of a malady killing honeybees using gene sequencing technology created by Roche Holding AG.

"What's not as well-known is that he set the stage for a whole series of projects which followed on the heels of the human genome sequence, and now are probably some of the most valuable studies ongoing in biomedical research,'' Vogelstein said. "The whole idea of having several labs undertake these projects is a different way of doing biomedical science, and you can largely attribute that to Francis as the leader.''

May 28, 2008

Mashups that use Flickr tags

Thus, there is a whole universe of images out there, from the community, filled with valuable tagged images.

Take a look at this mashup called Tag Galaxy. It’s using the tag data in the flickr images to organize them in almost any conceivable way. This is the universe of images tagged “car” + “night”. Just about any conceivable tag can be explored.

A Mashup that Elegantly searches Flickr images

Social networking: Does it really work?

Several months ago I posted a note about Sermo, the social networking site for physicians were you can post and exchange questions, ideas, comments, etc... The "My Space" for physicians as I have heard it called.  I also mentioned in that post reference to Medscape.  They have also entered the mix of social networking among doctors.  I received an e-mail recently which invited me to "join the new Medscape Physician Connect. Share your professional experiences, pose questions to other doctors and voice opinions in our new physician-only social community".  This is what I thought Sermo was. 

Nonetheless, I have been following the pathology discussions on both of these sites. While I may not necessarily agree with the comments or approaches, perhaps there may be some benefit to these types of discussions outside of formal meetings and peer-reviewed articles to acquire knowledge. 

I have reposted two recent discussions to illustrate the types of discussions if you are not familiar with these.  As you will see, a lot of this is where art meets science, and evidently there is more than one way to skin a cat.  I scrubbed the names and specialties from the posts and some of the responses are from the same ID but both include pathologists, surgeons, oncologists and radiation oncologists. 

It is interesting to see the kinds of responses from the different specialties and you can guess which are which.  Sometimes the responses are analytic, sometimes pragmatic, sometimes dogmatic. Look forward to your comments.

POST 1

Given the risk of false negatives for frozen sections/immediate cytology evaluation for breast sentinel lymph nodes, do you feel it is a viable option to instead eliminate such immediate assessments in favor of using only permanent specimens?
In your experience, do you feel the surgical community and patients will accept such a proposition?

#1 Is this the same thing as a touch prep?

#2 There really isn't any risk with a false negative....no foul no harm. The patient just gets a second procedure to do the completion ALND. (Which by what you are proposing everyone would get a second procedure if permanents are positive as opposed to just the ones that had a false negative by touch preps) What you are doing with touch preps is saving the person a second procedure and by what you are suggesting you are subjecting everyone to a second procedure that had a positive permanent that could have been avoided if a positive touch prep had been found. Actually I would be more concerned with a false positive as opposed to a false negative. We tend to do touch preps (not Frozen
sections)and if positive do an immediate ALND which saves the patient a 2nd operation and anesthesia and time off work. The patient's are informed that it is possible that a touch prep could be negative but be positive on permanent sections and if so then a second procedure to perform the ALND would be necessary. The key is to discuss the pros and con's with the patient and let them know that they shouldn't jump for joy and that they are not home free until the permanent sections are back. Most elect to have an immediate ALND if the touch prep is positive knowing full well that there is a possibility that the touch prep could be negative and the permanents positive which would then entail a second trip to the OR. They are also aware of a very small possibility of a false positive causing them to have an unnecessary ALND along with it's risks is positive knowing full well that there is a possibility that the touch prep could be negative and the permanents positive which would then entail a second trip to the OR.They are also aware of a very small possibility of a false positive causing them to have an unnecessary ALND along with it's risks .

False positives do cause concern because obviously no one wants the risks entailed with an unnecessary ALND(but heck that's what we did
all the time before Sentinel nodes were being done) I personally (knock on wood) haven't seen or heard of any false positives in my community.
If we were seeing false positives I doubt very many people would be doing any touch preps(or frozen sections) at all.

#3 1. This topic was recently discussed and,
2. False negatives are not the real problem, false positives would be.
I have not heard of a false positive, but it is certainly possible, particularly with touch preps. Germinal centers can show clustering of cells
and cytologic atypia that might be misinterpreted as metastatic ca. I tend to confirm suspicious touch preps with FS.

#4 So if you elect to skip immediate assessment (TP or FS), you will have to do a second procedure whenever axillary dissection is indicated on permanents; however, you will eliminate the possibility of a false positive diagnosis and unnecessary ALND.

#5 Agree with the above. I think most pathologists tend to err on the side of being conservative...that is, if there is something suspicious, but we are not confortable with calling it a met, we tell the surgeon to stop, knowing that the lesser evil is having to go back for a second procedure.

#6 Agree with above and on the patient surgical consent form, there is a place for the comment of "At your (the patient's) request, an intraoperative consutation will be performed on a sentinel lymph node. The results of this will dictate whether an axillary disection will be performed during this proceedure or will be deferred until a later date. You *the patient* are indicating that you understand this with your initials placed here_________"
Or something to that effect. This gives the surgeon a way to aleviate the patients concern after they awake as to why did you not finish the proceedure and in cases where the initial intraoperative evaluation was negative but the follow-up permanent sections was positive, the legal ramifications are covered.

#7 Let us not forget that even permanent sections have false negatives. The studies have been done decade after decade showing us that if a paraffin block which initially contains tissues that were grossed in by sectioning at every 2mm were to be sectioned completely thru the block, there could be as high as a 10% false negative rate. What would you recommend for for your family member knowing that statistic?

#8 That being said, if a touch prep and/or frozen section of a sentinal lymph node biopsy were to be positive it would indeed save the patient an added procedure. On the flip side, this all takes time which means additional time under anesthesia.

#8 Another point should be made regarding the use of frozen sections for any reason. That is, surgeons and pathologists both know that occasionally diagnoses change when permanent sections are examined. That being said, patients should be informed before surgery that the frozen section diagnosis could change when permanents are examined and the surgeon is actually using the frozen sections/touch prep approach as guidance for the surgery should there be usefull information gained with the frozen or touch prep.

#9 Knowledgeable surgeons accept the notion of false negative frozen sections or cytology preparations for these cases and are hopefully educating their patients. Given the relatively recent public hype on the subject and the usefulness of the assessment (saving women from unnecessarily extensive procedures or second operations), I cannot see surgeons or their patients accepting a change in the current practice. I agree with other postings that false positives would be a more significant issue. In my experience with five pathologists doing predominantly frozen sections on breast sentinel lymph nodes, false positives have been nonexistent (knock on wood) and false negatives uncommon with the most frequent "false negative" being the discovery of isolated tumor cells.

#10 The problem with sentinal LN is usually a false negative. It rarely happens but if it does happen, ALND can be performed in a latter procedure. In our practice we do touch prep as well as frozen section examination of entire lymph node (if size permits). We never had a false positive in our practice.

#11 Touch preps require special skills and are it is not hard to do a frozen section. I would repeat that I do not think we know yet the value of the sentinel node biopsy since there is not a standard protocol and follow up is still too short.

#12 It is my current practice to perform an intraoperative interpretation, and that would be my preference for myself or a family member.

#13 One could argue that the risk of a second general anesthaesia procedure may be higher than that of an unwarranted axillary sampling (I haven't seen a true 'dissection' in years, and hence risk of lymphedema, etc. are probably much lower than in the past).

#14 I feel only doing permanent sections would be safer for the patient and the clinician due to problems w/ both false positive and false negative immediate interpretations. Nevertheless, clinicians want to be able to do completion axillary disections at the same sitting if possible. A compromise we have adopted is to perform immediate interpretations only on larger, clinically and pathologically suspicious lymph nodes and add the caveat on negative interpretations that immediate evaluation reveals no evidence of metastatic tumor, but must await permanent sections for final interpretation.

#15 Intraoperative procedures are helpful in saving a second procedure if they are positive.
I believe that the type of intraoperative procedure should be left to the judgement of the pathologist and based primarily on the size of the node submitted with only touch preps done unless the node is sizeable.

#16 I'll add this comment as was stated on the other post. When evaluating a patient for breast surgery, the patient has an ultrasound guided core biopsy by me in my office at the initial visit unless the lesion is only microcalcifications. At the same visit, I examine the axilla of the involved side with ultrasound. Any nodes that are visible by ultrasound in the axilla are considered abnormal and I do a FNA of these. If the FNA is positive then I know pre-op that the patient needs an axillary dissection. If the FNA is negative, the patient gets a sentinal node biopsy with PERMANENT sections. Having to return to the OR for a positive sentinal node on permanents has been rare.

#17 I don't think false positive is a problem at daily practice and actually almost rarely seen.

#18 If frozen can make a definite dx, it saves pt to undergo 2nd procedure and save huge money in health care.

#19 We do touch preps instead of frozen sections.

#20 I think that the quality of the frozen sections depends upon the expertise of the doctor doing them,the number of cases that they handle daily and the quality of the equipment that is used. better quality is done at large volume centers ( e.g. Mayo clinic,NY Presbyterian, Memorial-Sloan Kettering). also if they have professional staff ( tech's) to cut them, then usually it is better than if house staff cut them. if they have docotrs trained in cutting breast then that is also better. also communication with the surgeaon is essential. no ivory tower pathologists unwilling to go into the OR to talk with the surgeon please. you go right in there and talk with them,esp. if margins are involved or the so-called sentinel node is needed.

#21 Go into the OR...hell, I get to scrub in on cases once in a while....yippeeeee!!!!

POST 2

27 y/o develops pelvic fullness and vaginal spotting. Thinking she might be pregnant, she goes to her local ob/gyn who finds what she thinks is a fibroid. D & C leads to a diagnosis of adenoca. Patient is staged, with further studies showing a single "hot spot" on PET scan at the mass, and patient is referred to a gynecologic oncologist who performs radical surgery (at a different hospital)

Final path report totally changes the tumor type. It's now being called a G2 leiomyosarcoma with epitheliod features; and it appears to be growing into the uterus from the round ligament. Nothing to suggest a uterine primary.

Recommendation from the out-of-area gyn-onc is six cycles of adjuvant doxorubicin/Iphosphamide/displatin.

We're not sure we agree with the use of chemo at all, and to make life more complex a chemoresistance assay was also performed -- showing that the tumor wasn't sensitive to anything.

So would you consider this a sarcoma that just happened to involve the uterus ?

If so would you give some variant of anthracycline/Ifex chemo, or would you hold that for relapse.

Would you consider whole pelvic RT +/- cisplatin ??

We did "pick" another brain, who suggested the RT, if we felt compelled to do "something".

#1 of 8
"So would you consider this a sarcoma that just happened to involve the uterus ?"
Yes - I think so, if the gross examination of the uterus revealed a dominant mass in the round ligament that focally invaded the uterine wall. I think we're in "rare tumor" land, where there will only be case reports of soft tissue sarcomas in the round ligament and not much help in guiding therapy. I think I would treat this as a soft tissue leiomyosarcoma arising in the pelvis/abdomen, if there is a standard treatment for that... Perhaps another pathologist will have more info....

#2 of 8
Not a uterine primary? As a long shot in the abdominal cavity, be sure you have ruled out gastrointestinal stromal tumor (GIST) which can look very much like epithelioid leiomyosarcoma. The reason: there is a good, specific potentially curative therapy for that, namely Gleevec. Immunostain to confirm: CD117 (c-kit)

#3 of 8
Good thought - I agree. Some GIST's will stain with muscle markers. You never know - they may have already done this...

#4 of 8
I'm pretty sure that the pathologists have considered GIST, but it doesn't hurt to ask them again. My partner would hate to miss something treatable

#5 of 8
A couple of thoughts from a gynecologic pathologist: from the description only, the tumor appears to be a round ligament derived epithelioid leiomyosarcoma. However, since we are including zebras in the differential herd, would consider the rare PEComa, which also has relatively reliable distinguishing immunostains, like GIST. Caveat, though, as soft tissue pathologists will tell you, CD117 positivity in any mesenchymal tumor does not necessarily mean it will respond to Gleevec.

#6 of 8
With the emphasis on the neoplasm apparently arising in the round ligament are we missing a different point in the original account: curettings diagnosed as adenocarcinoma (of the endometrium, I presume...it doesn't say exactly)? Have had cases of p53 factor related multiple focal origins in the female pelvic tissues: uterine leimoyosarcoma, plus adenocarcinoma of the endometrium, plus mixed mesodermal adenosarcoma, etc, etc. What was the review diagnosis on the curettings? I have seen several cases along these line which stayed localized and treatment limited to surgical excision was sufficient for a five year "free of tumor" assessment. What are the adverse possibilities of the chemotherapy?

#7 of 8
yes, rare. pecoma worth a thought, recent article in ajsp about pecoma vs leiomyosarcomas of gyn tract. may mimic epithelioid lms. should stain with hmb45/melanA but also may stain with muscle markers. not clear to me that these are separate entities.

#8 of 8
Everything has been considered in this case. If the tumor and affected organs have ben successfully surgically removed the patient need careful followup only at this time.

May 24, 2008

9th European Congress on Telepathology & 3rd International Congress on Virtual Microscopy

Somehow I forgot to announce and cover the 9th European Congress on Telepathology & 3rd International Congress on Virtual Microscopy held May 15th to 17th last week in Toledo, Spain.  Who knew there were at least 2 Toledos?  Looks like a beautiful venue.  A copy of the meeting guide can be found here

The European community has a long storied tradition of technologic and practice advances in the fields of telepathology and whole slide imaging.  It is encouraging to see increasing participation by vendors and leaders from South America and African and Asian continents as well. 

Here is the introduction from the program guide:

Information technology is helping pathologists in their clinical work, research activities, education, and quality assurance programmes. Since necessary technology is becoming increasingly complex, the
collaboration of Computer Science professionals, Informatics experts, or Information Technology and
Communication researchers is becoming increasingly necessary.

For that reason, the 9th European Congress on Telepathology and 3rd International Congress on Virtual Microscopy would like to become a forum to join together pathologists, biologists, information technology
professionals, including software engineers, computer science researchers, and any other biomedical informatics professional. They will have the opportunity to discuss their experiences with a broad range audience, from well-known pioneers to our young colleagues, and also including the industrial partners. This will be possible due to the maturity of this congress, after the success of the previous editions.

New European and International collaboration projects on telepathology, imaging and computing in general in Pathology, are being designed. These groups will have the opportunity to meet together during the 9th European Congress on Telepathology and 3rd International Congress on Virtual Microscopy, and create new
alliances with other related groups.

Be welcome to Toledo, one of world’s architectonical treasures, with magnificent monuments, especially from Moorish, Mudejar, Gothic and Renaissance periods. Surrounded by this historical environment we would like this congress to become a watchtower where we can foresee the emerging future of Pathology.

May 23, 2008

Breast Pathology White Paper

Breast Pathology Practices Whitepaper - Get more documents

May 22, 2008

Toshiba Imaging Partners with Olympus Canada to Offer New High Definition Clinical Microscopy System

Press Release - Toshiba America Imaging Systems Divison Release date: May 12, 2008

Toshiba_olympus

MAY 12, 2008 - Irvine, CA - Toshiba Imaging Systems Division (www.cameras.toshiba.com), a leader in advanced 3CCD color video imaging, is partnering with Olympus Canada (www.olympuscanada.ca) to offer a new tool for clinical pathology and teaching, the High Definition Synergy-HD Microscope Imaging System. After testing and evaluation of a number of systems, Olympus chose to integrate Toshiba's new ultra-compact IK-HD1 3CCD HDTV camera with its line of clinical microscopes that feature objectives and optics which are well suited for digital imaging. The system, which includes a hi-def, wide screen 42" or 47" 1080p LCD monitor, delivers video imagery in real time, displaying the entire slide at all ROIs and magnifications. Toshiba's camera and proprietary 3-chip prism block technology offers 1920 x 1080 pixel resolution at 30 frames per second with superb color reproduction, contrast and image detail without binning, image jitter or video lag. With the new HD format, the microscopy system offers exceptional detail, contrast and brightness even at low 2X / 4X magnifications where clinical screening and margins are performed. The image processing electronics in the HD camera system offers superior signal-to-noise ratio and unprecedented color image detail. A wide variety of adjustments, including the creation of custom color matrices and other user settings, is available via the compact, easy-to-use camera control unit. The commercial LCD display has a high refresh rate of 8 ms with superior broadcast quality HD-SDI video format of 1.4 Gb/s data rate. With high brightness and 60,000 hours of back light life span, the HD 1080i LCD display offers high contrast images that are viewable from any angle. Depending upon the need, an additional PC with an HD-SDI frame grabber can be added, allowing digital capture of the HD images at full 1920 x 1080 pixel resolution. The frame grabber allows simultaneous viewing of the microscopy slide image on the LCD monitor, making it ideal for tumor boards and clinical rounds as well as various medical and life science teaching environments.

Toshiba Imaging Systems Division (Irvine, CA) is the premier supplier of high quality video cameras for machine vision, R&D and scientific applications. Advanced video imaging technology and high resolution cameras such as Toshiba's 3CCD color cameras and their remote head camera family has earned Toshiba America's Imaging Systems Division the distinctive reputation for offering the most advanced imaging solutions to the industrial and scientific communities. Visit www.cameras.toshiba.com for more information. Olympus Canada, part of Tokyo-based Olympus Corporation ( www.olympuscanada.ca), provides sales and service for Olympus products in the medical, surgical, scientific and industrial markets in Canada. The company's mission is to serve the Canadian healthcare and commercial laboratory markets with integrated product solutions. Educational and consulting services team with the company's commitment to improving efficiencies in the healthcare system, providing customers with exceptional results and giving patients greater access to life-saving diagnostic procedures and treatments. For more information, please email: Tedd.Kelemen@olympus.com.

Study suggests some carbon nanotubes may increase risk of mesothelioma.

The Los Angeles Times (5/21, Zarembo) reports that "[c]ertain types of carbon nanotubes -- microscopic graphite cylinders used in a small, but growing, number of Space Age applications -- could pose a cancer risk similar to that of asbestos if inhaled," according to a study published online May 20 in the journal Nature Nanotechnology. Nanotubes, which "were discovered in the early 1990s,...have been billed as wonder particles for their incredible strength, low weight, and ability to conduct heat and electricity." Nevertheless, some experts have long "suspected that certain types of nanotubes could pose the same danger as asbestos fibers."

For the study, lead author Dr. Ken Donaldson, of the MRC/University of Edinburgh Centre for Inflammation Research, and colleagues, "tracked the short-term effects of various kinds of carbon nanotubes and asbestos fibers injected into the...abdomens" of mice, "near the mesothelium," according to the Washington Post (5/21, A2, Weiss). The "tissue surrounding the lungs and other organs" is typically "where certain kinds of asbestos fibers tend to migrate after being inhaled."

The researchers "injected four groups of mice: one with short nanotubes about five microns in length, one with long nanotubes about 20 microns in length, one with asbestos, and one with small carbon clumps," the New York Times (5/21, A22, Chang) adds. The authors found that rodents "injected with the short nanotubes or small carbon clumps did not develop disease." But, "[t]hose injected with long nanotubes or asbestos developed lesions on the tissue lining." Dr. Donaldson stated that "given more time, the lesions caused by the long nanotubes would have developed into mesothelioma."

Still, "the researchers said the link between long, straight, multi-walled carbon nanotubes and cancers was not proven," the BBC (5/20) explained. In fact, Dr. Donaldson noted, "We are a long way from saying that any form of carbon nanotubes causes mesothelioma."

The AFP (5/21) points out that "this is the first study to show that...carbon nanotubes can have the same damaging impact on the mesothelium" as asbestos. Study co-author Andrew Maynard said that the world is "at the very, very beginning of using these materials commercially." Therefore, "[g]reat caution must be exercised before introducing such products into the market if long-term harm is to be avoided," he added.

Due to the uncertainty posed by nanotubes, "the researchers hope to pressure companies developing carbon nanotube-based materials to reveal whether they are using longer strands such as the ones that appear to act like asbestos -- which was once a wonder material, too, before its cancerous consequences were discovered," the AP (5/21, Bergstein) reports. The San Francisco Chronicle (5/21, Fernholm) also covers the story.

Virtual Biopsy Can Tell Whether Colon Polyp Is Benign without Removal

Fewer normal colon biopsies on the horizon?

A probe so sensitive that it can tell whether or not a cell living within the human body is veering towards cancer development may revolutionize how future colonoscopies are done, say researchers from the Mayo Clinic in Jacksonville, Fla. 

Newswise — A probe so sensitive that it can tell whether or not a cell living within the human body is veering towards cancer development may revolutionize how future colonoscopies are done, say researchers from the Mayo Clinic in Jacksonville, Fla.

Investigators have found that technology known as a high resolution confocal endomicroscopy probe system can determine whether a colon polyp is benign (not precancerous) - without having to remove it for examination by a pathologist.

Their study, to be presented at the Digestive Disease Week, a scientific meeting of gastrointestinal specialists and researchers held in San Diego, shows that using the probe system was 89 percent accurate in identifying whether polyps were either precancerous or benign. But more importantly, it was correct 98 percent of the time in flagging polyps that were benign, which would then not need to be removed for biopsy. The Mayo researchers, who are the first in the U.S. to comprehensively test the system in the colon, believe they can push accuracy close to 100 percent with more research.

What this means is that the probe system can be used to during a colonoscopy to rule out removal of polyps that are not harmful, says the study’s senior author, Michael Wallace, M.D., M.P.H., Professor of Medicine at Mayo Clinic.
“Today, half of all polyps surgically removed during colonoscopy procedures are benign, and so this virtual biopsy will save time and expense, and reduce complications that can occur,” he says.

The device is a tiny imaging tool, only 1/16th of an inch in diameter, which can be attached to a variety of endoscopes that are already being used during colonoscopies, Dr. Wallace says. When a suspicious polyp is seen during a colonoscopy, a physician can use the probe to look closely at the lesion. To do this, a small amount of fluorescent contrast is used to illuminate the area, and the probe magnifies it by 1,000 times – enough to see a single red blood cell as it moves through a blood vessel.

In this study, the researchers first tested 10 precancerous (“adenomatous”) lesions as well as 10 benign (“hyperplastic”) lesions using the probe system in order to understand the differences in appearance between the two. (The status of the polyps was later verified by pathologists.) Among other things, they looked at changes in cell color and size, how nuclei within the cells looked, and whether cells were crowed within tissue, or fused.

They then, without knowledge of the pathologists’ diagnosis, used their new grading system to determine the status of 37 polyps within 25 patients, which were then removed. The most important clinical result is that the probe was 98 percent accurate in identifying lesions that were not cancerous. “That is what you want in a device like this,” says the project’s lead research fellow, Anna M. Buchner, M.D., who will be presenting the findings. “Removing a polyp that looks precancerous, but turns out to be benign, is okay, but you don’t want to leave polyps intact in the colon that are actually cancerous,” she says. “This probe is almost perfectly reliable in that regard and with more experience I am sure we can improve accuracy to nearly 100 percent.”

Wallace says the technology, which is also being tested in the esophagus, has the capacity to fundamentally change how many different endoscopy procedures are done. “This will shift our role from one of going in and getting tissue for a pathologist to examine to one in which we can do the pathology ourselves,” Dr. Wallace says. “This is instantaneous, real time pathology.”

The study was supported by the American Society for Gastrointestinal Endoscopy.

May 21, 2008

Aperio Opens Operations Center in Australia and New Zealand in Response to Global Demand for Digital Pathology Systems and Services

Recent press release from Aperio

Vista, CA – May 20, 2008 – Aperio Technologies, Inc., a global leader in digital pathology systems and services for the healthcare and life sciences industry, is pleased to announce the formation of its Australian and New Zealand operations center, headquartered in Brisbane. Bolstered by increasing demand for the company’s digital pathology solutions, Aperio’s expansion will be led by Howard Powell, national sales director, and will focus on providing sales, service, and marketing support across Australia and New Zealand.

This expansion is the latest in Aperio’s plans for continued global growth and the delivery of digital pathology solutions to customers worldwide. Aperio currently has an installed base of more than 375 systems in 25 countries, including more than two-thirds of the top 15 rated U.S. hospitals, leading academic medical centers and reference laboratories, and two-thirds of the top 15 pharmaceutical companies.

“In the last fiscal year, Aperio experienced more than 125% sales growth, an impressive figure that demonstrates how the emerging digital pathology market is resonating both nationally and globally,” said Dirk Soenksen, CEO of Aperio. “We are committed to building upon our success by selectively expanding Aperio’s global footprint in order to maximize our ability to understand and serve customers.”

Aperio’s digital pathology solutions enable users to achieve greater efficiency and cost savings by improving workflow processes and expanding data access, integration and reporting capabilities. Aperio’s patented linear array-based ScanScope® slide scanning systems are offered with Spectrum™ information management software to enable the viewing, analysis and management of digital slides and other images in a secure multi-user, multi-site environment, from anywhere, anytime.

The nature of Australia’s geography, with its large land mass separating numerous population centers, facilitates real time remote viewing and evaluation of digital slides by pathology experts, one of the key value propositions for digital pathology. The Royal College of Pathologists of Australia (RCPA), the official body governing the practice of pathology in Australia, is routinely using Aperio's ScanScope system to conduct proficiency testing throughout the country.

Educational Sponsors

Your email address:


Powered by FeedBlitz

Feeds

  • http://www.wikio.com

Medicine 2.0


Search

  • Google

    WWW
    tissuepathology.typepad.com

StumbleUpon

Technorati

  • Add to Technorati Favorites

Zimbio

Photo Atlas

Twitter Updates

    follow me on Twitter

    July 2009

    Sun Mon Tue Wed Thu Fri Sat
          1 2 3 4
    5 6 7 8 9 10 11
    12 13 14 15 16 17 18
    19 20 21 22 23 24 25
    26 27 28 29 30 31  

    Google Analytics

    Site Meter